Sorrento Therapeutics Inc (SRNE)

[dia76ca]

I love this PIPELINE(and so do Big Pharmas!). There are 8 programs in phase 3, pivotal or marketed! And 4 more in phase 2. Partnerships are coming with upfront, milestone and royalty payments. Revenues growing exponentially Quarter after Quarter. No wonder BlackRock has 22 million shares!

PIPELINE

Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases.

COVID-19 Programs

Key Programs:

*COVISTIX™ (diagnostic)FDA EUA

*COVIDROPS™ (treatment)Ph II

*COVI-AMG™ (treatment)Ph II

*COVISHIELD™ (treatment) Preclinical

*ABIVERTINIB (treatment)Ph III

*COVI-MSC (treatment)Ph III

*Mpro Inhibitor (oral pill) (anti-viral) Preclinical

*Omicron mRNA Vaccine (vaccine) Preclinical

Immunotherapy

Key Programs:

*Abivertinib (NSCLC) Ph III

*Abivertinib (B Cell Lymphomas) Ph II

*Abivertinib (Prostate) Preclinical

*Abivertinib (Lupus) Preclinical

*Abivertinib (MS) Preclinical

*Abivertinib (GvHD) Preclinical

*PD-L1 (Socazolimab)*(SCLC) Ph III

*PD-L1 (STI-3031)** (Cervical Cancer) Ph III

*CD47 (Solid Tumors) Ph I

*CD38 CAR-T (Multiple Myeloma) Ph I

*CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I

*TROP2 ADC* (Solid Tumors)
Ph I

*Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors)
PH I

*BCMA ADC (Liquid Tumors) Preclinical

*Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I

*Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I

*Rituximab-ADNAB™ (B-cell Lymphomas) Ph I

Pain

Key Programs:

*ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval

*SP-102 (Lumbar Radicular / Sciatica Pain) Ph III

*SP-103 (Acute Back Pain) Ph I

*SP-104 (Fibromyalgia) Preclinical

*RTX (resiniferatoxin) Epidural injection (Intractable Pain in Advanced Cancer) Ph II

*RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA Knee Pain) Ph II

Lymphatic Delivery

Key Programs:

*Sofusa® anti-TNF (Autoimmune RA) Ph I

*Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I

*Sofusa® anti-PD-1 (Melanoma) Ph I